11 Analysts Have This to Say About Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 11 analysts have published their opinion on Viridian Therapeutics (NASDAQ:VRDN) stock, with 4 bullish and 7 somewhat bullish ratings. The average 12-month price target is $46.0, with a high of $51.00 and a low of $40.00.
June 14, 2023 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
11 analysts have rated Viridian Therapeutics (NASDAQ:VRDN) stock over the past 3 months, with a majority being bullish. The average 12-month price target is $46.0.
The article mentions that 11 analysts have rated Viridian Therapeutics (NASDAQ:VRDN) stock over the past 3 months, with a majority being bullish or somewhat bullish. This indicates a positive sentiment towards the stock, which could lead to an increase in its price in the short term. The average 12-month price target of $46.0 also suggests potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100